FINWIRES · TerminalLIVE
FINWIRES

HKG:7666

8 stories mentioning HKG:7666Updated just now

Every FINWIRES story that references HKG:7666, newest first.

Asia

Metis TechBio Signs Up to $1.6 Billion Licensing Deal With Boulevard Bio

Metis TechBio (HKG:7666) entered into a global licensing agreement with Boulevard Bio, a U.S.-based biotechnology company under Deerfield Management, for its preclinical trispecific T-cell engager candidate MTS-128, according to a Tuesday Hong Kong bourse filing.The company will receive an upfront payment of $20 million and is eligible for up to $1.6 billion in development, regulatory and commercial milestone payments, plus tiered royalties on future product sales.Under the agreement, Boulevard Bio obtained exclusive global rights to develop, manufacture and commercialize MTS-128, a trispecific T-cell engager developed using Metis TechBio's AI-powered NanoForge platform.Shares of the firm were down nearly 2% in Tuesday afternoon trade.

HKG:7666
Asia

Metis TechBio Raises HK$304 Million From IPO Overallotment Exercise

Metis TechBio (HKG:7666) said its underwriters fully exercised the overallotment option for its Hong Kong initial public offering, while the stabilization period ended on June 5, according to a same-day filing with the Hong Kong bourse.The AI-driven nanotechnology company issued nearly 30.2 million H shares at HK$10.50 per share, generating additional net proceeds of about HK$304.2 million.The overallotment option was exercised after the same number of shares were over-allocated by the underwriters in the international offering.Metis TechBio said its public float remained in compliance with Hong Kong listing requirements following the exercise of the overallotment option.

HKG:7666
Asia

Metis TechBio Refutes Media Report on CSRC Supplemental Inquiry

Metis TechBio (HKG:7666) denied a media report alleging that China's securities regulator had issued supplemental information requests to the company, according to a Tuesday Hong Kong bourse filing.The AI-driven nanotechnology company said the report was "factually inaccurate and misleading."Metis TechBio said it received the China Securities Regulatory Commission's filing notice for its Hong Kong listing and H-share full circulation on March 17 and has not received any request from the regulator for supplemental information since then.

HKG:7666
Asia

Hong Kong Stocks Eke Out Gains; Metis TechBio, Impact Therapeutics Shine on Debut

Hong Kong stocks edged higher on Wednesday ahead of the meeting between U.S. President Donald Trump and Chinese President Xi Jinping.The Hang Seng Index added 0.2%, or 40.53 points, to close at 26,388.44. The Hang Seng China Enterprises Index barely moved in negative territory to finish at 8,876.38.Trump is expected to arrive in Beijing on Wednesday ahead of talks scheduled for Thursday and Friday.The leaders of the world's two largest economies are set to hold their first face-to-face meeting in more than six months.Discussions are expected to focus on Iran, Taiwan, artificial intelligence, and nuclear weapons, while both sides also weigh extending their critical minerals agreement.Meanwhile, tensions in the Middle East remained unresolved after Trump said he was unlikely to seek China's assistance in ending the conflict with Iran.In corporate news, two companies made their debut on the Hong Kong bourse.Metis TechBio (HKG:7666) closed nearly 127% higher at HK$23.80, well above the offer price of HK$10.50.Impact Therapeutics (HKG:7630) advanced over 108% to close at HK$41.86, compared with the offer price of HK$20.10.

Hang SengHKG:7630HKG:7666
Asia

Metis TechBio Soars 173% in Hong Kong Trading Debut

Metis TechBio's (HKG:7666) shares opened 173% above their initial public offering price during the company's Hong Kong debut on Wednesday morning.The China-based AI-driven nanotechnology company opened at HK$28.68 per share, well above the offer price of HK$10.50.

HKG:7666
Asia

Metis TechBio Raises Nearly HK$2 Billion From Hong Kong IPO Ahead of Debut

Metis TechBio (HKG:7666) raised HK$1.99 billion in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$10.50 per H-share, according to a Tuesday after-market filing with the Hong Kong Stock Exchange.The China-based AI-driven nanotechnology company offered 201.2 million H-shares in the global offering.The Hong Kong public offer was 6,910.96 times subscribed, with a final allocation of 40.2 million shares, representing 20% of the total offering.The international offering was 33.86 times subscribed, with a final allocation of 161 million shares, or 80% of the total offering.An over-allocation of 30.2 million shares was made under the global offering.Cornerstone investors, including BlackRock, UBS AM Singapore, China Venture Capital Innovation Investment Fund, Mirae, and HHLRA, were allotted a combined 110.4 million shares, representing 54.87% of the global offering, according to the filing.Metis TechBio is set to debut on the Hong Kong bourse on Wednesday, May 13.

HKG:7666
Asia

Hong Kong Stocks Slump As Middle East Fighting Escalates

Hong Kong equities fell Tuesday as bearish sentiment prevailed amid escalating tensions in the Middle East.The Hang Seng Index fell by around 197.27 points, or roughly 0.8%, to end at 25,898.61, while the Hang Seng China Enterprises Index decreased by 43.90 points, or around 0.5%, to close at 8,730.49.Fighting in the Middle East resumed as the U.S. and Iran vied for control of the critical Strait of Hormuz, after U.S. President Donald Trump said Washington would help ships stranded in the waterway, a key route that carried about one-fifth of global oil and LNG trade before the war.Iran had previously warned it would view any such action as a violation of a previously agreed ceasefire.The Middle East conflict will hit many Asia-Pacific corporate sectors through oil price hikes, shipping and supply chain disruptions, dampened demand, and delayed cyclical rebounds, Fitch Ratings said in a recent release.In corporate news, two firms filed to go public in Hong Kong.Metis TechBio (HKG:7666) is seeking to raise about HK$2.11 billion via the sale of 201.2 million shares at HK$10.50 per share. The Chinese AI-driven nanotechnology company will use funds to further research and development of AI infrastructure.Meanwhile, Impact Therapeutics (HKG:7630) launched its IPO to raise HK$913 million via the sale of 42 million shares at an indicative maximum price of HK$21.75 per share. The China-based biotechnology firm will use proceeds mainly to fund clinical development.Elsewhere, Star Sports Medicine (HKG:1609) had a stellar debut in Hong Kong. The medical device company's shares closed at HK$215 per share on their first day of trading, 118% above the offer price of HK$98.50.

Hang SengHKG:1609HKG:7630HKG:7666
Asia

Metis TechBio Seeks About HK$2.1 Billion in Hong Kong IPO

Metis TechBio (HKG:7666) launched its Hong Kong initial public offering on Tuesday, seeking to raise about HK$2.11 billion from the deal.The China-based AI-driven nanotechnology company is offering 201.2 million shares at HK$10.50 per share, according to a Hong Kong bourse filing.The offering comprises 10.1 million shares for Hong Kong investors and 191.2 million shares for international investors, subject to reallocation and the overallotment option.Allocation results are due by May 12, ahead of the company's planned trading debut on May 13.Net proceeds will be used mainly to fund research and development of AI infrastructure and nanomaterial platforms, as well as support clinical trials of pipeline products.The funds will also be used to expand into animal health and longevity solutions, build global operations, and for working capital and general corporate purposes.Jefferies Hong Kong, Deutsche Securities Asia, and CITIC Securities (Hong Kong) are acting as joint sponsors.Jefferies Hong Kong, Deutsche Bank AG (Hong Kong Branch), and CLSA are serving as overall coordinators and are also acting as joint bookrunners and joint lead managers, alongside CMB International Capital.Futu Securities International (Hong Kong) is acting as a joint bookrunner and joint lead manager.

HKG:7666

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:7666 in your portfolio
WheelAI
WheelAI
Analyze HKG:7666 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:7666